PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor.
PF-08046054 by Pfizer for Solid Tumor: Likelihood of Approval
PF-08046054 is under clinical development by Pfizer and currently in Phase I for Solid Tumor.